These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25442054)

  • 1. Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks.
    Parker C; De Bono J
    Eur Urol; 2015 Apr; 67(4):681-2. PubMed ID: 25442054
    [No Abstract]   [Full Text] [Related]  

  • 2. Steroids in prostate cancer: the jury is still out... and even more confused.
    Porta C; Bracarda S; Danesi R
    Eur Urol; 2015 Apr; 67(4):680-1. PubMed ID: 25465980
    [No Abstract]   [Full Text] [Related]  

  • 3. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer.
    Holder SL; Drabick J; Zhu J; Joshi M
    Cancer Biol Ther; 2015; 16(2):207-9. PubMed ID: 25756508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
    Venkitaraman R; Lorente D; Murthy V; Thomas K; Parker L; Ahiabor R; Dearnaley D; Huddart R; De Bono J; Parker C
    Eur Urol; 2015 Apr; 67(4):673-9. PubMed ID: 25457497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
    Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M
    BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer.
    Manenschijn L; Hamberg P
    Acta Oncol; 2016 May; 55(5):656-8. PubMed ID: 27046420
    [No Abstract]   [Full Text] [Related]  

  • 8. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
    Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 11. Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
    Biró K; Budai B; Szőnyi M; Küronya Z; Gyergyay F; Nagyiványi K; Géczi L
    Urol Oncol; 2018 Feb; 36(2):81.e1-81.e7. PubMed ID: 29153623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience with abiraterone.
    Dahut WL; Madan RA
    Lancet Oncol; 2014 Oct; 15(11):1188-90. PubMed ID: 25242047
    [No Abstract]   [Full Text] [Related]  

  • 13. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
    Cornel EB
    Eur Urol; 2012 Jun; 61(6):e59; author reply e60. PubMed ID: 22386192
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Conteduca V; Lolli C; De Giorgi U
    Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?
    Gartrell BA; Galsky MD
    Eur Urol; 2015 Feb; 67(2):231-2. PubMed ID: 25220371
    [No Abstract]   [Full Text] [Related]  

  • 17. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Bjartell A
    Eur Urol; 2015 Feb; 67(2):348-9. PubMed ID: 25760250
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to K. Lu.
    Fizazi K; Dreicer R
    J Clin Oncol; 2015 Oct; 33(28):3222. PubMed ID: 26215954
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to K. Lu.
    Morris MJ
    J Clin Oncol; 2015 Oct; 33(28):3222-3. PubMed ID: 26215948
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.